IVF · Stimulation strategy

Poor responder IVF — what to do when the ovaries do not respond as expected

A poor ovarian response to stimulation is one of the more disheartening situations in IVF. It can be predicted, it can be managed, and the choice of protocol matters. This page describes how poor response is defined (using the Bologna and POSEIDON criteria), what causes it, and the evidence-based strategies for getting the best outcome from a difficult cycle.

How poor response is defined

Two clinical frameworks are used. The Bologna criteria require any two of: advanced maternal age (≥40) or any risk factor for poor response; a previous poor response (≤3 oocytes with conventional stimulation); or an abnormal ovarian reserve test (AFC <5–7 or AMH <0.5–1.1 ng/mL). The POSEIDON criteria are more nuanced — they stratify patients by age and ovarian reserve markers into four groups, recognising that a young patient with low reserve and an older patient with low reserve are different clinical problems even though both qualify as “poor responders”.

Why poor response happens

• Age-related decline in ovarian reserve
• Premature ovarian insufficiency (genetic, autoimmune, idiopathic)
• Prior ovarian surgery (cyst removal, endometrioma excision)
• Chemotherapy or pelvic radiotherapy
• Endometriosis (a separate mechanism beyond surgery)
• Idiopathic in some patients with apparently normal reserve markers

Pre-cycle assessment

• AMH — cycle-day independent, reflects the residual antral follicle pool
• Antral follicle count (AFC) on baseline ultrasound
• Day-2 to day-3 FSH and oestradiol
• Thyroid function, prolactin
• Vitamin D, ferritin where supplementation might help
• Karyotype and fragile-X screening in younger patients with unexpectedly low reserve
• Realistic counselling about expected oocyte yield and the per-cycle success rate

Stimulation protocols

No single protocol works for every poor responder. The choice is individualised.

• Antagonist protocol with high-dose gonadotropin — the modern standard; flexible, lower risk of OHSS, often the right first try
• Long agonist protocol — some patients respond better with deeper suppression first; reasonable in selected cases
• Microdose flare — uses a microdose GnRH agonist to recruit follicles in the early follicular phase
• Mild stimulation — lower-dose protocol with the philosophy that quality matters more than quantity; appropriate for some patients
• Natural-cycle IVF or modified natural cycle — collects the single dominant follicle without stimulation; selected indication
• DuoStim (dual stimulation) — two stimulation rounds in the same menstrual cycle (one follicular, one luteal); maximises oocyte accumulation when time is critical
• Frozen oocyte or embryo accumulation — pooling oocytes or embryos across multiple cycles before transfer

Adjuvants — what the evidence actually says

Several adjuvants are promoted for poor responders. The honest evidence picture:

• DHEA — small RCTs suggest possible benefit on oocyte yield; not consistent. Often offered for 8–12 weeks before stimulation.
• CoQ10 — mechanistic rationale (mitochondrial function); RCT data limited but encouraging in some studies.
• Growth hormone — some meta-analyses show benefit on live birth in selected populations; expensive; offered selectively.
• Androgens (testosterone gel) — mixed evidence; selected use.
• Vitamin D supplementation — useful if deficient; benefit beyond correcting deficiency is unclear.
• Acupuncture, ovarian PRP, mitochondrial transfer — experimental; insufficient evidence to recommend.

Adjuvants are discussed openly, including their cost and the strength of evidence behind each.

Realistic counselling

Poor responders are counselled with explicit numbers, not vague reassurance. Per-cycle live birth rates are lower; cumulative success across multiple cycles is closer to reasonable. The conversation includes: probability of acceptable oocyte yield, probability of a viable embryo, probability of live birth per cycle and cumulatively, the option of donor egg if cycles do not succeed, and the timeline of repeat attempts.

We do not promise outcomes. We do show the data.

When to refer for a second opinion

• One or more cycles with very low oocyte yield despite high-dose stimulation
• A diagnosis of poor response without an individualised protocol re-think
• Pressure to move directly to donor egg without a structured discussion
• Age 35–40 with falling AMH and limited time to plan

Guidelines we follow on this topic

• ESHRE Guideline on Ovarian Stimulation 2019/2023
• POSEIDON Group consensus on suboptimal response
• ASRM committee opinion on poor responders
• NICE fertility guidance

Related reading

• IVF programme overview
• The IVF process
• Fertility preservation
• Endometriosis programme
• PCOS
• Menstrual cycle physiology

Poor ovarian response should not be treated as failure. Individualised protocols (POSEIDON criteria, mild stimulation, dual stimulation, accumulation of oocytes/embryos) extend the chance of live birth even in expected poor responders.

CONTINUE READING

Explore the IVF Programme

Poor Responder IVF is one part of the broader IVF and fertility programme. The main IVF pillar covers individualised protocols, success counselling, and long-term reproductive planning.

Individualised IVF and fertility planning with honest, evidence-based counselling — and realistic expectations from the very first consultation.

Book a consultation

Dr. Priyadatt Patel

Senior Gynecologist · Advanced Laparoscopic Surgeon · IVF and Endometriosis Programme Lead

MS OBGyn · Pregnancy Care · Advanced Gynaecological Ultrasound · Fertility Preservation

ESHRE / ESGE / AAGL / ASRM guideline-aligned practice. 3D Karl Storz precision technique. Fertility-preservation-first philosophy. Evidence-based decisions, honest counselling, long-term outcomes orientation.